Immunotherapy for Cure: advancing HIV remission and eradication
Official title: I4C 2.0: Immunotherapy for Cure
Funded at Beth Israel Deaconess Medical Center · NIH-11515079 · Data updated 2026-11-12
A large, multi-year program will explore immune-based strategies to achieve long-term HIV control without daily ART, with input from researchers, industry, government, and the community.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 16, 2021 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $4,653,643 |
| NIH project number | 4UM1AI164556-06 |
| Project ID | NIH-11515079 on NIH RePORTER |
Who could benefit from this research
✓Could help
People living with HIV who could participate in future immunotherapy trials or receive information about novel remission strategies.
✕Less likely to help
Individuals not eligible for immunotherapy trials or who do not respond to immune-based strategies may see no direct benefit.
What this research studies
This program brings together researchers from multiple sectors to study how the immune system can target and control HIV. It includes projects on understanding the viral reservoir, developing immune-based therapies like vaccines and engineered immune cells, and testing combinations that could lead to ART-free remission. By studying both nonhuman primates and humans, the team aims to identify signatures of persistence and rebound and to move promising approaches toward clinical development. Community engagement and strong management support ensure the research stays focused on patient impact and feasibility.
Why it matters
Potential benefit: If successful, this work could lead to durable HIV remission or eradication strategies that reduce or eliminate the need for daily antiretroviral therapy.
How similar studies have gone: Prior research shows immune-based approaches can modulate HIV persistence, but achieving durable remission remains a major challenge and is still being tested.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Barouch, Dan H. — Beth Israel Deaconess Medical Center
- Study coordinator: Barouch, Dan H.
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.